Organization | Gruppo Italiano Studio Linfomi

Gruppo Italiano Studio Linfomi Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Modena Italy (1988)

Organization Overview

First Clinical Trial

2000

NCT00435955

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2010

Timeline

NOW

Now

Alternative names

Gruppo Italiano Studi Linfomi

Active Ingredients

Drugs in Phase 3 Trials (15)

bleomycin (blenoxane) (1 trial)

carmustine (bicnu) (1 trial)

cyclophosphamide (cytoxan) (4 trials)

cytarabine (cytosar-u) (1 trial)

doxorubicin (Doxil) (2 trials)

etoposide (vepesid) (2 trials)

interferon alpha-2b (Intron-A) (1 trial)

melphalan (alkeran) (2 trials)

peripheral blood hematopoietic cell (3 trials)

prednisone (meticorten) (3 trials)

procarbazine (matulane) (1 trial)

rituximab (rituxan) (5 trials)

sargramostim (leukine) (1 trial)

urea (2 trials)

vincristine (oncovin) (2 trials)

Drugs in Phase 2 Trials (6)

bendamustine (treanda) (2 trials)

bortezomib (velcade) (1 trial)

fludarabine (fludara) (1 trial)

lenalidomide (revlimid) (2 trials)

palonosetron (aloxi) (1 trial)

thalidomide (Thalomid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Aggression (Phase 2)

Hodgkin Disease (Phase 3)

Lymphoma (Phase 3)

Lymphoma, Follicular (Phase 3)

Lymphoma, Mantle-Cell (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Multiple Myeloma (Phase 2)

Nausea (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Vomiting (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 11
# of Trial APIs: 21